153 related articles for article (PubMed ID: 38496910)
1. RT-PCR assay to detect
Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ
Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910
[TBL] [Abstract][Full Text] [Related]
2. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.
Schittenhelm J; Ziegler L; Sperveslage J; Mittelbronn M; Capper D; Burghardt I; Poso A; Biskup S; Skardelly M; Tabatabai G
Neurooncol Pract; 2021 Apr; 8(2):209-221. PubMed ID: 33898054
[TBL] [Abstract][Full Text] [Related]
4. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
5. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
6. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
7. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
Gött H; Uhl E
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
[TBL] [Abstract][Full Text] [Related]
8. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
9. Extra-CNS and dural metastases in
Kleinschmidt-DeMasters BK; Gilani A
Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked.
Nassar AH; Lundgren K; Pomerantz M; Van Allen E; Harshman L; Choudhury AD; Preston MA; Steele GS; Mouw KW; Wei XX; McGregor BA; Choueiri TK; Bellmunt J; Kwiatkowski DJ; Sonpavde GP
JCO Precis Oncol; 2018; 2():. PubMed ID: 33604498
[TBL] [Abstract][Full Text] [Related]
11. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
12. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of an RNA Sequencing Assay for Gene Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tumors.
Peng H; Huang R; Wang K; Wang C; Li B; Guo Y; Li M; Zhang D; Dong H; Chen H; Chen C; Xu Q; Li F; Tian L; Wu J
J Mol Diagn; 2021 Feb; 23(2):223-233. PubMed ID: 33271368
[TBL] [Abstract][Full Text] [Related]
15. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
16. Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.
Lanic MD; Le Loarer F; Rainville V; Sater V; Viennot M; Beaussire L; Viailly PJ; Angot E; Hostein I; Jardin F; Ruminy P; Laé M
Mod Pathol; 2022 May; 35(5):649-663. PubMed ID: 35075283
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens.
Haley L; Parimi V; Jiang L; Pallavajjala A; Hardy M; Yonescu R; Morsberger L; Stinnett V; Long P; Zou YS; Gocke CD
J Mol Diagn; 2021 Oct; 23(10):1343-1358. PubMed ID: 34358677
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]